Abstract
Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-over-expressing cells, respectively.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1002/(sici)1097-0215(20000415)86:2<295::aid-ijc22>3.0.co;2-k
Copy DOIJournal: International journal of cancer | Publication Date: Mar 28, 2000 |
Citations: 33 |
Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-over-expressing cells, respectively.
Join us for a 30 min session where you can share your feedback and ask us any queries you have